Developments in Acute Lymphoblastic Leukemia Following ASH 2024 - Episode 2

AlloHCT Outcomes From ECOG ACRIN E1910 in Newly Diagnosed, MRD-Negative B-Lineage ALL

,

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on alloHCT outcomes from the ECOG ACRIN E1910 trial of blinatumomab.

EP. 1: Frontline Treatment Considerations in Adult and Pediatric Acute Lymphoblastic Leukemia
Now Viewing
EP. 2: AlloHCT Outcomes From ECOG ACRIN E1910 in Newly Diagnosed, MRD-Negative B-Lineage ALL
EP. 3: Adding Blinatumomab to Consolidation Therapy in Older Patients With Newly Diagnosed, BCR::ABL1–Negative B-ALL
EP. 4: Approaching First-Line Treatment Decisions in Pediatric ALL
EP. 5: Blinatumomab Plus Chemo in Newly Diagnosed, Standard-Risk Pediatric B-ALL
EP. 6: Mitigation and Management Strategies for ICANS and Other AEs in ALL
EP. 7: Incorporating Blinatumomab into Clinical Practice for ALL
EP. 8: Ongoing Research to Watch in Acute Lymphoblastic Leukemia

Related Content:

Developments in Acute Lymphoblastic Leukemia Following ASH 2024USC Norris Comprehensive Cancer CenterHematologic Oncology
Ongoing Research to Watch in Acute Lymphoblastic Leukemia
Incorporating Blinatumomab into Clinical Practice for ALL
Mitigation and Management Strategies for ICANS and Other AEs in ALL